Emerging Biopharmaceutical Organization Awards $1.2 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Infor
27 May 2004 - 12:01AM
PR Newswire (US)
Emerging Biopharmaceutical Organization Awards $1.2 Million Study
to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Thorough Phase I ECG Study For
Key Compound to Be Performed Over 90-Day Period PHILADELPHIA, May
26 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a
leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has
received an agreement for $1.2 million in cardiac safety monitoring
and services from an emerging biopharmaceutical organization for
one of its drug candidates in clinical development. The agreement
covers an extensive Phase I study for which eRT is providing
comprehensive support including the provision, training and ongoing
assistance required for effective use of digital 12-lead Holter
equipment designed to facilitate 24-hour digital recording of
cardiac safety data that is subsequently provided to eRT for
analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
The study is targeted for completion over a 90-day period. "eRT's
comprehensive approach to Thorough Phase I ECG studies, including a
state-of-the-art 12-lead continuous ECG recording platform, expert
scientific consultation, and partnerships with leading Clinical
Pharmacology units, are proving important to emerging organizations
striving to attain Best Practices in cardiac safety for their new
drug development programs," said Scott Grisanti, senior vice
president of business development and chief marketing officer at
eRT. "We are pleased that our investments in infrastructure,
systems, and programs have enabled the scalability and throughput
required to offer our services to all segments of the new drug
development industry, including organizations, such as this
sponsor, developing novel therapies in areas of unmet need." Based
in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.ert.com/) is a provider of technology and services to
the pharmaceutical, biotechnology and medical device industries on
a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden of
Hayden Communications, +1-858-456-4533, for eResearchTechnology Web
site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles